BILL ANALYSIS                                                                                                                                                                                                    �



                                                                  AB 1743
                                                                  Page  1


          ASSEMBLY THIRD READING
          AB 1743 (Ting)
          As Introduced February 14, 2014
          Majority vote 

           HEALTH              13-6                                        
           
           -------------------------------- 
          |Ayes:|Pan, Ammiano, Atkins,     |
          |     |Bonilla, Gordon, Chesbro, |
          |     |Gomez, Gonzalez, Roger    |
          |     |Hern�ndez, Nazarian,      |
          |     |Ridley-Thomas,            |
          |     |Wieckowski, Skinner       |
          |     |                          |
          |-----+--------------------------|
          |Nays:|Maienschein, Ch�vez,      |
          |     |Mansoor, Nestande,        |
          |     |Patterson, Wagner         |
          |     |                          |
           -------------------------------- 
           SUMMARY  :  Deletes the limit on the number of syringes a  
          pharmacist or physician can sell to an adult without a  
          prescription and deletes the sunset date of January 1, 2015,  
          that would end the statewide authorization to sell syringes  
          without a prescription, as specified.

           FISCAL EFFECT  :  None

           COMMENTS  :  According to the author, the intent of this bill is  
          to improve access to syringes and hypodermic needles so as to  
          remove significant barriers for persons seeking to protect their  
          health and the health of other persons, and to remove barriers  
          for programs or businesses to provide sterile injection  
          equipment and education to adults, thereby reducing the spread  
          of communicable diseases and protecting public health.  The  
          author notes, without this bill, persons living in many parts of  
          California will not have safe syringe access.  At the end of  
          this year, the state will revert back to a piecemeal framework  
          adopted in 2005 in which counties or cities (with their own  
          departments of health) can decide if pharmacists may sell  
          syringes over the counter.  The author states this would mean  
          safe, over the counter syringes would only be available through  
          pharmacists in 15 counties and four cities participating in the  








                                                                  AB 1743
                                                                  Page  2


          disease prevention demonstration projects (DPDP), in addition to  
          needle exchange programs operational in only 19 counties and two  
          cities.  The author concludes that a statewide solution is best  
          because diseases do not stay confined to local borders - county  
          lines or city limits.

          California is one of only five states having statewide  
          limitations on the purchase of syringes, according to a 2014  
          survey by the National Association of Boards of Pharmacy (NABP).  
           Although statewide sales are currently legal, there is a  
          restriction as to the number.

          California has allowed the sale of hypodermic needles and  
          syringes for almost 10 years.  SB 1159 (Vasconcellos), Chapter  
          608, Statutes of 2004, established a five-year pilot program to  
          allow California pharmacies, when authorized by a local  
          government, to sell up to 10 syringes to adults without a  
          prescription.  Within several years there were hundreds of  
          pharmacies participating, reaching a total of 650 by the  
          suspension of the pilot.  The pilot was suspended when statewide  
          sales were authorized by SB 41 (Yee), Chapter 738, Statutes of  
          2011.  SB 41 also required the Department of Public Health (DPH)  
          to evaluate the results of the pilot project.

          In July 2010, DPH published an evaluation of the pilot.  The  
          report had a number of findings. Among the most relevant were  
          that an increased number of intravenous drug users (IDUs)  
          reported using pharmacies as a source of their syringes.  The  
          availability of these sterile syringes seemed to impact  
          behavior.  A significantly lower portion of IDUs reported  
          sharing of syringes and there was no evidence of increased  
          unsafe discarding of used hypodermic needles or syringes  
          observed in the DPDPs.  DPH reported that the rate of injection  
          of illegal drugs decreased among publicly funded human  
          immunodeficiency virus (HIV) testing clients.  The report also  
          found that drug-related crime remained stable in the  
          jurisdictions that authorized DPDPs.  Nevertheless, DPH  
          concluded that the program appeared to be having the desired  
          effect of augmenting access to sterile syringes.  

          The most important statistic would be the HIV and acquired  
          immunodeficiency syndrome (AIDS) incidence rates.  DPH states  
          that between problems of data gathering and the short duration  
          of the projects made the infection rate impossible to measure  








                                                                  AB 1743
                                                                  Page  3


          accurately.  However, there are a host of studies both  
          domestically and internationally that provide evidence that  
          provision of sterile hypodermic needles and syringes reduces HIV  
          transmission.
             
          Public health experts, including the Centers for Disease Control  
          and Prevention, have identified access to sterile syringes as  
          one component of a comprehensive HIV prevention strategy  
          designed to reduce HIV transmission among IDUs.  In the last 10  
          years, a number of national organizations have endorsed  
          deregulation to allow IDUs to purchase and possess syringes and  
          needles without a prescription, including the American Medical  
          Association, the American Pharmaceutical Association, the NABP,  
          the National Alliance of State and Territorial AIDS Directors,  
          and the Association of State and Territorial Health Officials.

          The Drug Policy Alliance and San Francisco AIDS Foundation,  
          cosponsors of this bill, argue this bill will continue  
          cost-effective HIV and hepatitis prevention policy in  
          California.  By lifting the current sunset and allowing  
          pharmacists and physicians the discretion to furnish sterile  
          syringes, this will be an important part of the state's  
          comprehensive approach to preventing the spread of HIV,  
          hepatitis B, and hepatitis C.  They note over 200 studies from  
          the United States and abroad concur that improved syringe access  
          reduces the rate of syringe sharing and disease transmission  
          without increasing rates of drug use, drug injection, or crime.   
          The cosponsors also note that maintaining access to sterile  
          syringes reduces costs to taxpayers; the cost of treating one  
          case of HIV can exceed $600,000.

          Supporters note that California was one of the last states to  
          relax restrictions on accessing a sterile syringe, leading to an  
          unnecessarily high rate of syringe-acquired HIV, hepatitis B,  
          and hepatitis C.  They argue since the enactment of SB 41,  
          pharmacists have been free to protect the health of individual  
          patients and the community health at no cost to taxpayers.  They  
          support this bill because it will make the discretion permanent  
          and allow the pharmacists or physicians to decide on how many  
          syringes can be provided.
                
           The California Narcotic Officers Association and the California  
          Police Chiefs Association oppose this bill arguing there is no  
          evidence to justify an outright lifting of the sunset or a  








                                                                  AB 1743
                                                                  Page  4


          removal of the current cap of 30 syringes.
           

          Analysis Prepared by  :    Roger Dunstan / HEALTH / (916) 319-2097  

                                                                FN: 0003090